Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma
This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.
Authors
- Esra Bilir (ORCID: https://orcid.org/0000-0003-4499-6543)
- Zoia Razumova (ORCID: https://orcid.org/0000-0001-6598-0896)
- Michael Leonard Friedlander (ORCID: https://orcid.org/0000-0003-3090-795X)
- David D.L. Bowtell (ORCID: https://orcid.org/0000-0001-9089-7525)
- Christian Appenzeller‐Herzog (ORCID: https://orcid.org/0000-0001-7430-294X)
- Nicolò Bizzarri (ORCID: https://orcid.org/0000-0002-1727-904X)
- Viola A Heinzelmann-Schwarz (ORCID: https://orcid.org/0000-0002-5613-8629)
- Madawa Jayawardana (ORCID: https://orcid.org/0000-0002-6990-1785)
- Joanna Kacperczyk‐Bartnik (ORCID: https://orcid.org/0000-0003-2539-3894)
- Tibor A. Zwimpfer (ORCID: https://orcid.org/0000-0002-1574-6572)
- Dale W. Garsed (ORCID: https://orcid.org/0000-0003-1223-0121)
- Hannah Ewald (ORCID: https://orcid.org/0000-0002-5081-1093)
Institutions
- Koç University (TR)
- The University of Melbourne (AU)
- University of Basel (CH)
- Medical University of Warsaw (PL)
- Peter MacCallum Cancer Centre (AU)
- University Hospital of Basel (CH)
- Agostino Gemelli University Polyclinic (IT)
- Karolinska Institutet (SE)
- Prince of Wales Hospital (AU)
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1002/14651858.cd015896
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- European Society for Medical Oncology